Test Price
2,800 AED✅ Home Collection Available
CCM2 Gene Sequencing for Cerebral Cavernous Malformations Type 2 (Genetic Test) in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CCM2 للتشوهات الكهفية الدماغية من النوع الثاني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary | الملخص التنفيذي
This ISO 9001:2015‑certified NGS test delivers 99.9% diagnostic sensitivity for CCM2 mutations, the inherited cause of familial cerebral cavernous malformations type 2. يكشف هذا الاختبار الجيني عن طفرات CCM2 المسؤولة عن التشوهات الكهفية الدماغية الوراثية بدقة 99.9% بموجب شهادة الآيزو 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing.
- Premium Logistics: Paid Hospital‑Grade Home Collection by ISO‑certified Cold‑Chain Home Collection; VIP Mobile Phlebotomy available 8 AM – 11 PM.
- Clinical Guidance: Complimentary telephonic post‑test clinical guidance on result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
What is CCM2 Gene Sequencing?
This Next‑Generation Sequencing (NGS) test analyses the entire coding region of the CCM2 gene, identifying pathogenic variants responsible for cerebral cavernous malformations type 2—a familial neurovascular disorder marked by brain capillary‑venous malformations that can haemorrhage. يساعد هذا الفحص الجيني في تحديد الطفرات المسببة للتشوهات الوعائية الدماغية من النوع الثاني، وهو اضطراب وراثي يؤدي إلى نزيف دماغي.
| Feature | Our CCM2 NGS Test | Closest Alternative (Gene Panel / Sanger) |
|---|---|---|
| Methodology | Full‑gene NGS (Illumina® platform) | Targeted Sanger sequencing or multi‑gene panel |
| Variant Detection | SNVs, indels, copy‑number variants; >99.9% sensitivity | Limited to pre‑defined hotspots; may miss large rearrangements |
| Turnaround Time | 3–4 weeks | 3–6 weeks (often sequential reactions) |
| ISO Accreditation | ISO 9001:2015 certified | Variable; often externally unverified |
| Price in UAE | 2800 AED | Typically 3500‑4500 AED |
Physician Insight & Safety Protocol
“Genetic testing for CCM2 is a powerful preventive tool in families with known cavernous malformations; however, a positive result must always be correlated with detailed neuroimaging and clinical examination by a neurologist or medical geneticist. Please, never stop or adjust your anti‑epileptics or blood‑thinning medications without a full consultation with your treating physician.”
— Dr. PRABHAKAR REDDY, DHA License 61713011, Consultant Medical Geneticist
Clinical Safety Exclusion & Red Flag Alerts
- Exclusion criteria: Recent blood transfusion (< 2 weeks), active systemic infection, pregnancy (requires additional counselling).
- Emergency red flags after blood draw: Sudden severe headache, seizure, focal weakness, vision loss, or speech difficulty – go to the nearest ER immediately.
- Never discontinue prescribed medication: Do not stop any prescribed medication, especially anticoagulants or anti‑epileptics, without direct doctor approval.
Frequently Asked Questions
Who should consider CCM2 genetic testing?
Individuals with multiple cerebral cavernous malformations detected on MRI or a confirmed family history of CCM2‑related disease should undergo testing. يجب أن يخضع للفحص الأشخاص الذين تظهر لديهم تشوهات كهفية دماغية متعددة بالرنين المغناطيسي أو تاريخ عائلي مؤكد لمرض CCM2.
What sample is required and how is it collected?
A simple blood draw (3‑5 mL in EDTA tube), or a single drop of blood dried on an FTA card; extracted DNA is also accepted. Our VIP phlebotomy team provides home collection within 60 minutes across all Emirates. يتم جمع عينة دم بسيطة (3‑5 مل في أنبوب EDTA) أو قطرة دم واحدة على بطاقة FTA، ويقوم فريق السحب المنزلي لدينا بالزيارة خلال 60 دقيقة في جميع الإمارات.
How will I receive my results and what support is offered?
A secure PDF report is delivered within 3–4 weeks, accompanied by a complimentary tele‑genetic counselling session to explain variant classification and clinical implications. يتم تسليم تقرير PDF آمن خلال 3‑4 أسابيع مع جلسة استشارة وراثية هاتفية مجانية لشرح التصنيف الجيني والآثار السريرية.
2026 Medical Coding & Regulatory Compliance: This is mapped to ICD‑10‑CM Q28.3 (Cerebral cavernous malformations), Z82.3 (Family history of cerebrovascular disease), Z15.89 (Genetic susceptibility to other disease). LOINC code: 92966-6. All procedures comply with Federal Decree‑Law No. 41 of 2024 (Art. 87), UAE Child Data Sovereignty Law 2026 (CDS Law for minors), and UAE PDPL. Facility License: 9834453. ISO 9001:2015 Certification INT/EGQ/2509DA/3139.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians